Lampalizumab fails to prevent geographic atrophy growth

Investigators report data from 2 randomized phase 3 trials assessing the safety and efficacy of lampalizumab, a complement factor D inhibitor, for the treatment of geographic atrophy.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553